Evidence supporting the use of: Serrapeptase
For the health condition: Blood Clots (prevention of)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Serrapeptase, an enzyme originally derived from the silkworm, has been studied for its potential fibrinolytic (clot-dissolving) and anti-inflammatory properties. The rationale for using serrapeptase to support the prevention or treatment of blood clots is based on its ability to break down fibrin, a protein involved in the formation of blood clots and scar tissue. Several in vitro and animal studies have demonstrated serrapeptase’s capacity to reduce fibrin and help dissolve blood clots. For example, a few animal studies from the 1980s and 1990s showed that serrapeptase could decrease the size of experimentally induced thrombi (blood clots), and some Japanese clinical reports have suggested benefits in conditions like chronic venous insufficiency and inflammation where fibrin deposition is an issue.

However, robust human clinical trials evaluating serrapeptase specifically for the prevention or treatment of blood clots are lacking. Most available human data are limited to small studies or case reports, and often focus on related outcomes such as swelling, pain, or post-surgical recovery rather than direct prevention of thromboembolic events. As a result, while there is some scientific rationale and preliminary evidence suggesting serrapeptase may have fibrinolytic effects, the overall quality and quantity of clinical evidence is low. Major medical organizations do not currently recommend serrapeptase for the prevention or treatment of blood clots, and more rigorous research is needed.

More about Serrapeptase
More about Blood Clots (prevention of)

Products containing Serrapeptase

We currently have no products on Vitabase that contain this ingredient.